Abstract 15991: Associations of Pentraxin-3 With Cardiovascular Events, Incident Heart Failure and Mortality Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study
Background: Pentraxin-3 (PTX3) is an inflammatory marker thought to be more specific to vascular inflammation than C-reactive protein (CRP). Whether PTX3 is independently associated with adverse events among persons with stable coronary heart disease (CHD), and whether kidney dysfunction influences this association, is not known.
Methods: We evaluated the associations of baseline PTX3 levels with all-cause mortality, cardiovascular events (myocardial infarction, stroke or CHD death), and incident heart failure during 37 months among ambulatory persons with stable CHD participating in the Heart and Soul Study. Cox proportional hazards models were adjusted for age, sex, race, hypertension, diabetes, smoking, and CRP.
Results: Among 986 persons with stable CHD, each one unit increase in log PTX3 was associated with an 80% increased risk of all-cause mortality (HR 1.8, 95% CI 1.5-2.1), a 50% increased risk of cardiovascular events (HR 1.5, 95% CI, 1.2-1.9), and an 80% greater risk of incident heart failure (HR 1.8, 95% CI, 1.3-2.5). Further adjustment for estimated glomerular filtration rate (eGFR) attenuated (but did not eliminate) these associations to 1.6 (1.3-1.9) for mortality, 1.3 (1.0-1.6) for CV events and 1.5 (1.1-2.1) for incident heart failure. Stratification by eGFR above or below 60 ml/min/m2 did not affect these associations (p interaction > 0.3 for all outcomes).
Conclusions: Among persons with stable CHD, higher PTX3 concentrations were associated with increased risk for all cause death, CVD events and incident HF independently of systemic inflammation. Adjustment for eGFR modestly attenuated these associations, suggesting that future studies of PTX3 should adjust for kidney function.
- © 2011 by American Heart Association, Inc.